Anaphylatoxin C3a receptors in asthma
Respiratory Research volume 6, Article number: 19 (2005)
The complement system forms the central core of innate immunity but also mediates a variety of inflammatory responses. Anaphylatoxin C3a, which is generated as a byproduct of complement activation, has long been known to activate mast cells, basophils and eosinophils and to cause smooth muscle contraction. However, the role of C3a in the pathogenesis of allergic asthma remains unclear. In this review, we examine the role of C3a in promoting asthma. Following allergen challenge, C3a is generated in the lung of subjects with asthma but not healthy subjects. Furthermore, deficiency in C3a generation or in G protein coupled receptor for C3a abrogates allergen-induced responses in murine models of pulmonary inflammation and airway hyperresponsiveness. In addition, inhibition of complement activation or administration of small molecule inhibitors of C3a receptor after sensitization but before allergen challenge inhibits airway responses. At a cellular level, C3a stimulates robust mast cell degranulation that is greatly enhanced following cell-cell contact with airway smooth muscle (ASM) cells. Therefore, C3a likely plays an important role in asthma primarily by regulating mast cell-ASM cell interaction.
Role of complement system in the development of asthma
Asthma, a complex airway inflammatory disease, is characterized by bronchoconstriction, airway hyperresponsiveness (AHR) and remodeling. Current consensus suggests that TH2 cytokine producing T cells, mast cells and ASM cells play central roles in the pathogenesis of asthma [1–7]. The complement system forms an important part of innate immunity against bacteria and other pathogens. As a system of 'pattern recognition molecules', foreign surface antigens and immune complexes initiate a proteolytic pathway leading to the formation of a lytic membrane attack complex. The anaphylatoxins C3a and C5a are released as byproducts of complement activation and modulate innate immunity. Accordingly, C5a is involved in a number of inflammatory diseases such as immune-complex-mediated lung injury and sepsis [8, 9]. A role for C3a in innate or adaptive immunity, however, has only been recently recognized .
C3a levels are elevated in bronchoalveolar lavage (BAL) fluid after segmental allergen challenge in asthmatic but not healthy subjects [11–14]. Furthermore, plasma C3a is also elevated in acute exacerbations of asthma . Additionally, single nucleotide polymorphisms in C3 and C3a receptor genes increases susceptibility to asthma . Collectively, these findings suggest that C3a and the cognate G protein coupled receptor (C3aR) may play a role in the development of airway hyperresponsiveness (AHR) and inflammation.
C3a receptors in models of Airway Hyperresponsiveness
Studies with animal models provided compelling evidence for C3aR activation in the development of AHR and inflammation. Humbles et al., , showed that C3aR (-/-) mice in BALB/c strain are protected from AHR in response to aerosolized ovalbumin challenge following intraperitoneal sensitization with ovalbumin . However, C3aR (-/-) mice developed normal airway inflammatory response with no difference in TH2 cytokine production and eosinophil recruitment in BAL when compared to wild-type mice. Additionally, guinea pigs with a natural defect in C3aR expression were also protected from AHR in response ovalbumin to challenge with no effect on airway inflammation . These initial findings suggested that C3a modulates AHR, perhaps, via a direct action on airway smooth muscle cells [12, 17, 18].
Recent studies using C3aR (-/-) mice provided new insights on the role of C3a on both AHR and airway inflammation . When sensitized intraperitoneally with extracts of Aspergillus fumigatous and challenged intranasally with allergen, these mice experienced substantial decreases in both AHR and airway eosinophilia relative to wild-type mice. Furthermore, BAL levels of TH2 cytokines (IL-4, IL-5, IL-13), IgE titres and mucous production were all significantly reduced in C3aR (-/-) mice. Allergen-challenged C3 (-/-) mice also display diminished AHR, lung eosinophilia and TH2 cytokine production when compared to wild-type mice . These findings support a role of C3a receptors in the development of AHR and inflammation. However, the effect of C3aR on different phases of AHR models may depend on the nature of the allergen, method of sensitization and the strain of mice used.
C3a generation in asthma
Increased level of C3a in BAL of subjects with asthma implies a potential role for this apaphylatoxin in promoting airway inflammation. However, the cells responsible for C3a generation and the airway effector cells stimulated by C3a remain unknown. Plausibly, antibody generated during antigen sensitization may interact with allergen to activate the classical complement pathway. Additionally, airway epithelial cells and pulmonary macrophages secrete both C3 and several components of the alternate pathway of complement (factors B, H, and I and properdin) [21–23]. Thus, activation of alternative or the lectin pathway on the allergen may also lead to the generation of C3a. It is noteworthy that house dust mite protease, allergenic extracts of Aspergillus fumigatous and mast cell tryptase also activate the complement pathway directly [13, 24–26]. Thus, combination of different pathways likely generates C3a in the airway of individuals with asthma (Figure 1).
C3a has little effect on allergen sensitization in models of AHR
Both antigen-presenting cells (APCs) and activated T cells express C3aR [27–30], raising the possibility C3a may regulate sensitization phase of allergic asthma. Kawamoto et al , recently used wild-type and C3aR-/- mice to characterize the immune response to C3a. Convincingly, C3aR deficiency had little effect on TH2 cytokine response to intraperitoneal ovalbumin sensitization. Furthermore, C3a had no effect on TH2 cytokine production in response to T cell receptor ligation. Further, Taube et al.,  showed that administration of complement inhibitor in mice after sensitization but before allergen challenge prevented the development of AHR and blocked TH2 cytokine production and lung inflammation. Additionally, a small molecule antagonist of C3a receptor, when administered after sensitization but before challenge also caused significant inhibition of airway inflammation . These findings suggest that the effect of C3a on the development of allergic AHR may not involve modulation of the sensitization phase of the disease.
Relationship between C3aR and FcεRI in mast cell activation in asthma
Mast cells appear to play a pivotal role in the development of AHR and inflammation . The ability of allergen to cross-link high affinity IgE receptors (FcεRI) on mast cells to induce degranulation and leukotriene generation is well documented [35, 36]. Surprisingly, the role of C3a in mast cell activation remains controversial and appears to depend on the mast cells subtype. For example, murine bone marrow-derived mast cells and a rat basophilic leukemia, RBL-2H3 cells, which have been used extensively as mast cell models, do not express C3a receptors . In contrast, C3a receptors are expressed in human CD34+-derived primary mast cell cultures [38, 39], human mast cell lines HMC-1 [40, 41] and LAD 2  as well as murine pulmonary mast cells (Thangam, B and Ali, H, unpublished data). Interestingly, C3a is one of the most potent mast cell chemoattractants known [42, 43]. C3a also induces robust mast cell degranulation [38, 39] and leukotriene C4 generation (Thangam, B and Ali, H, unpublished data). These findings suggest that allergen induces mast cell degranulation by at least two mechanisms: cross-linking of FcεRI and via C3a generation following complement activation by allergen protease (Figure 2). Mast cell proteases also activate the complement pathway to generate C3a . Therefore, C3a generation following FcεRI aggregation may amplify mast cell mediator release (Figure 2).
Mast cell-ASM interaction in asthma
Recent studies with immunohistological analysis of bronchial biopsy specimens from subjects with asthma and those from patients with eosinophilic bronchitis provided important insight on the role of mast cell-ASM cell interaction in the development of AHR in asthma [4, 44, 45]. Asthma and eosinophilic bronchitis are characterized by similar inflammatory infiltrates in the submucosa of the lower airway. However, ASM infiltration by mast cells is a feature of asthma and not eosinophilic bronchitis. This difference in mast cell recruitment in asthma is associated with AHR, which is absent in in eosiniphilic bronchitis . Furthermore, degranulated mast cells are detected in greater number in ASM bundles of patients who died from asthma when compared to non-asthmatic control . Based on these findings, new hypothesis suggests that increased mast cell recruitment and interaction with ASM may promote release of mast cell-derived mediators that modulate resident airway cell function is asthma [4, 5, 44].
ASM is not only a contractile tissue that responds to mast cell-derived mediators in asthma, but also modulates mast cell function and airway inflammation. ASM cells express stem cell factor (SCF), which induce mast cell chemotaxis, survival and differentiation [47, 48]. Interleukin-1β, tumor necrosis factor (TNF) and TH2 cytokines IL-4 and IL-13 derived cytokines also stimulate ASM to express a large number of chemokines and cytokines [49–52]. Thus, activated ASM cells secrete chemokines and cytokines that may recruit and retain mast cells into the ASM.
C3a receptors and mast cell-ASM cell interaction
C3a has long been recognized as an agent that evokes force generation in smooth muscle. In guinea pigs, C3a-induced contraction of lung parenchyma may involve indirect effects of histamine and arachidonic acid metabolites . In mice, C3a does not cause shortening of isolated tracheal strips . Furthermore, C3a fails to induce AHR after intratracheal instillation in naïve mice . In contrast, in mice immunized with house dust mite, subsequent intratracheal administration of C3a stimulates both AHR and airway inflammation . These findings suggest that C3a-induced AHR and bronchoconstriction requires enhanced infiltration and activation of inflammatory cells, likely mast cells.
Recently, investigations showed that human mast cells but not human or murine ASM express C3aR . Interestingly, incubation of mast cells with human ASM cells, but not its culture supernatant, significantly enhanced C3a-induced mast cell degranulation. Although stem cell factor (SCF) and its receptor c-kit are constitutively expressed on ASM cells and mast cells respectively, neutralizing antibodies to SCF and c-kit failed to inhibit ASM cell-mediated enhancement of mast cell degranulation. Dexamethasone-treated ASM cells however normally express cell surface SCF but were significantly less effective in enhancing C3a-induced mast cell degranulation when compared to untreated cells. Collectively, these findings suggest that cell-cell interaction between ASM cells and mast cells, via a SCF-c-kit independent but dexamethasone-sensitive mechanism, enhances C3a-induced mast cell degranulation, which likely regulates ASM function and may contribute to the pathogenesis of asthma.
While mast cells and ASM cell interaction plays a role in AHR, airway inflammation in asthma is strongly linked to TH2 lymphocyte and their cytokines IL-4, IL-5 and IL-13. These cytokines play key roles in the recruitment and activation of eosinophil, mucous production and IgE synthesis. Allergen challenge of sensitized C3 (-/-) and C3aR (-/-) mice decreased production of TH2 cytokines in BAL and substantially reduced recruitment of T cells, eosinophils and neutrophils in lung tissue [19, 20]. Furthermore, inhibition of complement activation or administration of C3aR antagonist during the effector phase of asthma substantially inhibited airway inflammation [32, 33]. These findings suggest activation of C3aR is required for TH2 effector function in murine model of allergen-induced inflammation. Accordingly, in human mast cells, C3a stimulates the production of MCP-1, RANTES , IL-8 and IL-13 (Thangam, B and Ali, H, unpublished data)-cytokines and chemokines are responsible for the recruitment of T lymphocytes, eosinophils and neutrophils into the airway. Further, C3aR are expressed on basophils, eosinophils and bronchial epithelial cells [18, 54–57]. Thus, interaction of a number of inflammatory and resident cells likely regulate C3a-dependent TH2 cytokine and chemokine production in asthma (Figure 3).
Accumulating evidence suggests that C3a may play an important role in the pathogenesis of asthma. In murine models of allergic AHR and inflammation, inhibition of complement activation or small molecule antagonists of C3a receptor after sensitization but before allergen challenge inhibits airway responses. Furthermore, cell-cell interaction between ASM cells and mast cells enhances C3a-induced mast cell degranulation, which likely regulates ASM function, thus contributing to the pathogenesis of asthma. Further investigations on cellular and molecular mechanisms by which C3a modules mast cell-ASM interactions may offer novel therapeutic approaches to the treatment of asthma and airway inflammation.
airway hyperresponsiveness: ASM, airway smooth muscle
Amrani Y, Panettieri RA: Airway smooth muscle: contraction and beyond. Int J Biochem Cell Biol 2003, 35:272–276.
Howarth PH, Knox AJ, Amrani Y, Tliba O, Panettieri RAJ, Johnson M: Synthetic responses in airway smooth muscle. J Allergy Clin Immunol 2004, 114:S32–50.
Panettieri RAJ: Airway smooth muscle: immunomodulatory cells that modulate airway remodeling? Respir Physiol Neurobiol 2003, 137:277–293.
Robinson DS: The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? J Allergy Clin Immunol 2004, 114:58–65.
Brightling CE, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID, Bradding P: Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma. Clin Exp Allergy 2003, 33:1711–1716.
Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID: Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002, 346:1699–1705.
Rivera J: Molecular adapters in Fc(epsilon)RI signaling and the allergic response. Curr Opin Immunol 2002, 14:688–693.
Huber-Lang MS, Riedeman NC, Sarma JV, Younkin EM, McGuire SR, Laudes IJ, Lu KT, Guo RF, Neff TA, Padgaonkar VA, Lambris JD, Spruce L, Mastellos D, Zetoune FS, Ward PA: Protection of innate immunity by C5aR antagonist in septic mice. Faseb J 2002, 16:1567–1574.
Shushakova N, Skokowa J, Schulman J, Baumann U, Zwirner J, Schmidt RE, Gessner JE: C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest 2002, 110:1823–1830.
Hawlisch H, Wills-Karp M, Karp CL, Kohl J: The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 2004, 41:123–131.
Nakano Y, Morita S, Kawamoto A, Suda T, Chida K, Nakamura H: Elevated complement C3a in plasma from patients with severe acute asthma. J Allergy Clin Immunol 2003, 112:525–530.
Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, Gerard NP, Gerard C: A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000, 406:998–1001.
Castro FF, Schmitz-Schumann M, Rother U, Kirschfink M: Complement activation by house dust: reduced reactivity of serum complement in patients with bronchial asthma. Int Arch Allergy Appl Immunol 1991, 96:305–310.
Krug N, Tschernig T, Erpenbeck VJ, Hohlfeld JM, Kohl J: Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 2001, 164:1841–1843.
Hasegawa K, Tamari M, Shao C, Shimizu M, Takahashi N, Mao XQ, Yamasaki A, Kamada F, Doi S, Fujiwara H, Miyatake A, Fujita K, Tamura G, Matsubara Y, Shirakawa T, Suzuki Y: Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. Hum Genet 2004, 115:295–301.
Bautsch W, Hoymann HG, Zhang Q, Meier-Wiedenbach I, Raschke U, Ames RS, Sohns B, Flemme N, Meyer Zu Vilsendorf A, Grove M, Klos A, Kohl J: Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma [In Process Citation]. J Immunol 2000, 165:5401–5405.
Gerard NP, Gerard C: Complement in allergy and asthma. Curr Opin Immunol 2002, 14:705–708.
Drouin SM, Kildsgaard J, Haviland J, Zabner J, Jia HP, McCray PBJ, Tack BF, Wetsel RA: Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol 2001, 166:2025–2032.
Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA: Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2002, 169:5926–5933.
Drouin SM, Corry DB, Kildsgaard J, Wetsel RA: Cutting edge: the absence of C3 demonstrates a role for complement in Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2001, 167:4141–4145.
Vandermeer J, Sha Q, Lane AP, Schleimer RP: Innate immunity of the sinonasal cavity: expression of messenger RNA for complement cascade components and toll-like receptors. Arch Otolaryngol Head Neck Surg 2004, 130:1374–1380.
Varsano S, Kaminsky M, Kaiser M, Rashkovsky L: Generation of complement C3 and expression of cell membrane complement inhibitory proteins by human bronchial epithelium cell line. Thorax 2000, 55:364–369.
Strunk RC, Eidlen DM, Mason RJ: Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J Clin Invest 1988, 81:1419–1426.
Nagata S, Glovsky MM: Activation of human serum complement with allergens. I. Generation of C3a, C4a, and C5a and induction of human neutrophil aggregation. J Allergy Clin Immunol 1987, 80:24–32.
Maruo K, Akaike T, Ono T, Okamoto T, Maeda H: Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease. J Allergy Clin Immunol 1997, 100:253–260.
Schwartz LB, Kawahara MS, Hugli TE, Vik D, Fearon DT, Austen KF: Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J Immunol 1983, 130:1891–1895.
Gutzmer R, Lisewski M, Zwirner J, Mommert S, Diesel C, Wittmann M, Kapp A, Werfel T: Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons. Immunology 2004, 111:435–443.
Kirchhoff K, Weinmann O, Zwirner J, Begemann G, Gotze O, Kapp A, Werfel T: Detection of anaphylatoxin receptors on CD83+ dendritic cells derived from human skin. Immunology 2001, 103:210–217.
Soruri A, Kiafard Z, Dettmer C, Riggert J, Kohl J, Zwirner J: IL-4 down-regulates anaphylatoxin receptors in monocytes and dendritic cells and impairs anaphylatoxin-induced migration in vivo. J Immunol 2003, 170:3306–3314.
Werfel T, Kirchhoff K, Wittmann M, Begemann G, Kapp A, Heidenreich F, Gotze O, Zwirner J: Activated human T lymphocytes express a functional C3a receptor. J Immunol 2000, 165:6599–6605.
Kawamoto S, Yalcindag A, Laouini D, Brodeur S, Bryce P, Lu B, Humbles AA, Oettgen H, Gerard C, Geha RS: The anaphylatoxin C3a downregulates the Th2 response to epicutaneously introduced antigen. J Clin Invest 2004, 114:399–407.
Taube C, Rha YH, Takeda K, Park JW, Joetham A, Balhorn A, Dakhama A, Giclas PC, Holers VM, Gelfand EW: Inhibition of complement activation decreases airway inflammation and hyperresponsiveness. Am J Respir Crit Care Med 2003, 168:1333–1341.
Baelder R, Fuchs B, Bautsch W, Zwirner J, Kohl J, Hoymann HG, Glaab T, Erpenbeck V, Krug N, Braun A: Pharmacological Targeting of Anaphylatoxin Receptors during the Effector Phase of Allergic Asthma Suppresses Airway Hyperresponsiveness and Airway Inflammation. J Immunol 2005, 174:783–789.
Taube C, Wei X, Swasey CH, Joetham A, Zarini S, Lively T, Takeda K, Loader J, Miyahara N, Kodama T, Shultz LD, Donaldson DD, Hamelmann EH, Dakhama A, Gelfand EW: Mast cells, FcepsilonRI, and IL-13 are required for development of airway hyperresponsiveness after aerosolized allergen exposure in the absence of adjuvant. J Immunol 2004, 172:6398–6406.
Andrade MV, Hiragun T, Beaven MA: Dexamethasone suppresses antigen-induced activation of phosphatidylinositol 3-kinase and downstream responses in mast cells. J Immunol 2004, 172:7254–7262.
Furumoto Y, Nunomura S, Terada T, Rivera J, Ra C: The FcepsilonRIbeta immunoreceptor tyrosine-based activation motif exerts inhibitory control on MAPK and IkappaB kinase phosphorylation and mast cell cytokine production. J Biol Chem 2004, 279:49177–49187.
Erdei A, Andrasfalvy M, Peterfy H, Toth G, Pecht I: Regulation of mast cell activation by complement-derived peptides. Immunol Lett 2004, 92:39–42.
Woolhiser MR, Brockow K, Metcalfe DD: Activation of human mast cells by aggregated IgG through FcgammaRI: additive effects of C3a. Clin Immunol 2004, 110:172–180.
Venkatesha RT, Thangam EB, Zaidi AK, Ali H: Distinct regulation of C3a-induced MCP-1/CCL2 and RANTES/CCL5 production in human mast cells by extracellular signal regulated kinase and PI3 kinase. Mol Immunol 2005, 42:581–587.
Ali H, Ahamed J, Hernandez-Munain C, Baron JL, Krangel MS, Patel DD: Chemokine production by G protein-coupled receptor activation in a human mast cell line: roles of extracellular signal-regulated kinase and NFAT. J Immunol 2000, 165:7215–7223.
Ahamed J, Venkatesha RT, Thangam EB, Ali H: C3a Enhances Nerve Growth Factor-Induced NFAT Activation and Chemokine Production in a Human Mast Cell Line, HMC-1. J Immunol 2004, 172:6961–6968.
Nilsson G, Johnell M, Hammer CH, Tiffany HL, Nilsson K, Metcalfe DD, Siegbahn A, Murphy PM: C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 1996, 157:1693–1698.
Hartmann K, Henz BM, Kruger-Krasagakes S, Kohl J, Burger R, Guhl S, Haase I, Lippert U, Zuberbier T: C3a and C5a stimulate chemotaxis of human mast cells. Blood 1997, 89:2863–2870.
Page S, Ammit AJ, Black JL, Armour CL: Human mast cell and airway smooth muscle cell interactions: implications for asthma. Am J Physiol Lung Cell Mol Physiol 2001, 281:L1313–23.
Berger P, Girodet PO, Begueret H, Ousova O, Perng DW, Marthan R, Walls AF, Tunon de Lara JM: Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis. Faseb J 2003, 17:2139–2141.
Carroll NG, Mutavdzic S, James AL: Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J 2002, 19:879–885.
Kassel O, Schmidlin F, Duvernelle C, Gasser B, Massard G, Frossard N: Human bronchial smooth muscle cells in culture produce stem cell factor. Eur Respir J 1999, 13:951–954.
Tsujimura T: Role of c-kit receptor tyrosine kinase in the development, survival and neoplastic transformation of mast cells. Pathol Int 1996, 46:933–938.
Ammit AJ, Lazaar AL, Irani C, O'Neill GM, Gordon ND, Amrani Y, Penn RB, Panettieri RAJ: Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: modulation by glucocorticoids and beta-agonists. Am J Respir Cell Mol Biol 2002, 26:465–474.
Oltmanns U, Issa R, Sukkar MB, John M, Chung KF: Role of c-jun N-terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from human airway smooth muscle cells. Br J Pharmacol 2003, 139:1228–1234.
Song R, Ning W, Liu F, Ameredes BT, Calhoun WJ, Otterbein LE, Choi AM: Regulation of IL-1beta -induced GM-CSF production in human airway smooth muscle cells by carbon monoxide. Am J Physiol Lung Cell Mol Physiol 2003, 284:L50–6.
Faffe DS, Whitehead T, Moore PE, Baraldo S, Flynt L, Bourgeois K, Panettieri RA, Shore SA: IL-13 and IL-4 promote TARC release in human airway smooth muscle cells: role of IL-4 receptor genotype. Am J Physiol Lung Cell Mol Physiol 2003, 285:L907–14.
Stimler NP, Bloor CM, Hugli TE: C3a-induced contraction of guinea pig lung parenchyma: role of cyclooxygenase metabolites. Immunopharmacology 1983, 5:251–257.
Thangam BE, Venkatesha RT, Zaidi AK, Jordan-Sciutto KL, Goncharov DA, Krymskaya VP, Amrani Y, Panettierijn RA, Ali H: Airway smooth muscle cells enhance C3a-induced mast cell degranulation following cell-cell contact. Faseb J 2005., In Press:
Daffern PJ, Pfeifer PH, Ember JA, Hugli TE: C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 1995, 181:2119–2127.
Elsner J, Oppermann M, Czech W, Dobos G, Schopf E, Norgauer J, Kapp A: C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 1994, 24:518–522.
Bischoff SC, de Weck AL, Dahinden CA: Interleukin 3 and granulocyte/macrophage-colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a. Proc Natl Acad Sci U S A 1990, 87:6813–6817.
This work was supported by National Institutes of Health grants 1RO1-HL63372 and 2RO1-HL-55301. We are grateful to Drs. Asifa K Zaidi and E. Berla Thangam for critical review of this manuscript.
The author(s) declare that they have no competing interests.
About this article
Cite this article
Ali, H., Panettieri, R.A. Anaphylatoxin C3a receptors in asthma. Respir Res 6, 19 (2005). https://doi.org/10.1186/1465-9921-6-19
- Mast Cell
- Airway Inflammation
- Airway Smooth Muscle
- Stem Cell Factor